WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206465
CAS#: 2025320-97-0 (HCl)
Description: Lifirafenib, also known as Beigene-283, is a Novel potent and selective RAF Kinase and EGFR inhibitor. BGB-283-displays Potent Antitumor Activity in B-RAF Mutated Colorectal Cancers. In vitro, BGB-283 potently inhibits B-RAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harbouring B-RAFV600E and EGFR mutation/amplification. In B-RAFV600E CRC cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell-line derived and primary human colorectal tumor xenografts bearing B-RAFV600E mutation. BGB-283 as a potent antitumor drug candidate with clinical potential for treating CRC harbouring B-RAFV600E mutation.
MedKoo Cat#: 206465
Name: Lifirafenib HCl
CAS#: 2025320-97-0 (HCl)
Chemical Formula: C26H19ClF3N3O3
Exact Mass: 478.12528
Molecular Weight: 513.9012
Elemental Analysis: C, 60.77; H, 3.73; Cl, 6.90; F, 11.09; N, 8.18; O, 9.34
Lifirafenib HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: BGB-283; BGB 283; BGB283; Beigene-283; Beigene283; Beigene 283; Lifirafenib
IUPAC/Chemical Name: 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one hydrochloride
InChi Key: VIZZONBMKQWTRV-NYTZCTPBSA-N
InChi Code: InChI=1S/C26H18F3N3O3.ClH/c27-26(28,29)13-2-1-12-9-18(31-17(12)10-13)23-22-16-11-14(3-5-19(16)35-24(22)23)34-20-7-8-30-25-15(20)4-6-21(33)32-25;/h1-3,5,7-11,22-24,31H,4,6H2,(H,30,32,33);1H/t22-,23-,24-;/m0./s1
SMILES Code: O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=CC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1.[H]Cl
The following data is based on the product molecular weight 513.9012 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Tang Z, Yuan X, Du R, Cheung SH, Zhang G, Wei J, Zhao Y, Feng Y, Peng H, Zhang
Y, Du Y, Hu X, Gong W, Liu Y, Gao Y, Liu Y, Hao R, Li S, Wang S, Ji JF, Zhang LH,
Li S, Sutton D, Wei M, Zhou C, Wang L, Luo L. BGB-283, a Novel RAF Kinase and
EGFR inhibitor, Displays Potent Antitumor Activity in B-RAF Mutated Colorectal
Cancers. Mol Cancer Ther. 2015 Jul 24. pii: molcanther.0262.2015. [Epub ahead of
print] PubMed PMID: 26208524.